A detailed history of Cm Management, LLC transactions in Cytosorbents Corp stock. As of the latest transaction made, Cm Management, LLC holds 800,000 shares of CTSO stock, worth $776,000. This represents 1.01% of its overall portfolio holdings.

Number of Shares
800,000
Previous 850,000 5.88%
Holding current value
$776,000
Previous $595,000 101.68%
% of portfolio
1.01%
Previous 0.55%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$0.7 - $1.55 $35,000 - $77,500
-50,000 Reduced 5.88%
800,000 $1.2 Million
Q2 2024

Aug 01, 2024

BUY
$0.7 - $1.01 $17,500 - $25,250
25,000 Added 3.03%
850,000 $595,000
Q1 2024

May 14, 2024

BUY
$0.86 - $1.07 $352,600 - $438,700
410,000 Added 98.8%
825,000 $783,000
Q4 2023

Feb 12, 2024

SELL
$1.08 - $1.94 $37,800 - $67,900
-35,000 Reduced 7.78%
415,000 $460,000
Q1 2023

May 08, 2023

SELL
$1.79 - $4.17 $44,750 - $104,250
-25,000 Reduced 5.26%
450,000 $1.52 Million
Q4 2022

Feb 09, 2023

SELL
$1.03 - $2.03 $206,000 - $405,999
-200,000 Reduced 29.63%
475,000 $736,000
Q3 2022

Nov 04, 2022

BUY
$1.2 - $2.46 $90,000 - $184,500
75,000 Added 12.5%
675,000 $918,000
Q2 2022

Aug 08, 2022

BUY
$1.76 - $3.22 $440,000 - $805,000
250,000 Added 71.43%
600,000 $1.31 Million
Q1 2022

May 09, 2022

BUY
$2.88 - $4.23 $144,000 - $211,500
50,000 Added 16.67%
350,000 $1.12 Million
Q4 2021

Feb 02, 2022

BUY
$4.05 - $8.11 $506,250 - $1.01 Million
125,000 Added 71.43%
300,000 $1.26 Million
Q3 2021

Nov 08, 2021

BUY
$7.0 - $9.71 $175,000 - $242,750
25,000 Added 16.67%
175,000 $1.42 Million
Q2 2021

Aug 10, 2021

BUY
$7.55 - $9.42 $226,500 - $282,600
30,000 Added 25.0%
150,000 $1.13 Million
Q1 2021

May 12, 2021

BUY
$8.23 - $11.48 $987,600 - $1.38 Million
120,000 New
120,000 $1.04 Million

Others Institutions Holding CTSO

About Cytosorbents Corp


  • Ticker CTSO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 43,577,400
  • Market Cap $42.3M
  • Description
  • Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...
More about CTSO
Track This Portfolio

Track Cm Management, LLC Portfolio

Follow Cm Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cm Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cm Management, LLC with notifications on news.